Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Inventiva S.A.NASDAQ: IVA

Accounts Payables · Q4 FY2025 · quarter ended Dec 2025

Accounts payables turns negative

Q4 FY2025 accounts payables was -€5.31M, compared with €0 a year earlier. Over 3 fiscal years it compounded at -11.4% a year.

Context

  • Accounts payables amounted to 54.8% of revenue in FY2025, up 54.8 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-€5.31M— QoQ
Last fiscal yearDec 2025
€2.46M— YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR-11.4%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

EUR · from the cash flow

Latest · FY2025
2.46M EUR
Year-over-year change
—
4-year CAGR
-24.6%

Accounts Payables vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Accounts payables amounts to 54.8% of revenue for IVA, versus a peer median of 12.0%.
IVA Competitors
Accounts Payables for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVVDInvivyd, Inc.LTM Mar 2026$6.72M USD-188.7%—12.0%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$3.31M USD+280.1%+21.9%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$3.06M USD-161.7%—9.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$2.51M USD+12.5%—1116.0%
IVAInventiva S.A.FY2025€2.46M EUR—-11.4%54.8%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$443K USD-6.7%+126.3%25.0%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$399K USD+1230.0%-34.4%0.6%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$370K USD-77.8%—3.3%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$325K USD+38.3%-33.1%550.8%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$262K USD+132.6%-50.3%—
Peer median (excluding IVA) —+12.5%-33.1%12.0%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Depreciation & Amortization(1.29M)1.7M2.6M5.2M3.22M
Deferred Income Tax(3.27M)(5.26M)(4.74M)(4.8M)(2.3M)
Stock-Based Compensation2.09M2.22M3.97M3.58M26.77M
Change in Working Capital979K5.71M17.31M1.68M6.42M
Accounts Receivables(5.32M)3.84M(5.84M)2.81M816.45K
Inventory(72K)19K(44K)417K0
Accounts Payables7.6M3.54M20M02.46M
Other Working Capital(1.23M)(1.69M)3.19M(1.54M)3.15M
Other Non-Cash Items3.5M4.98M9.68M92.63M205.07M
Operating Cash Flow(47.63M)(44.93M)(81.61M)(85.93M)(100.98M)
Capital Expenditures(534K)(561K)(540K)(333K)(237.26K)
Acquisitions (Net)89K41K000
Purchases of Investments(1.35M)(1K)(8.3M)0(127.69M)
Sales of Investments(89K)9.39M978K9.08M0
Other Investing Activities90K1K131K75.72K(1K)
Investing Cash Flow(1.79M)8.87M(7.73M)8.75M(127.93M)
Debt Repayment(28K)28.44M(4.1M)19.92M(5.98M)
Common Stock Issued25.48M8.83M28.08M57.34M237.74M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(17.73K)(772.47K)5.1M68.33M236.98K
Financing Cash Flow25.45M37.27M29.08M145.59M232M
Effect of Forex Changes4.84M(1.03M)445K1.24M11.08M
Net Change in Cash(19.13M)183K(59.82M)69.65M14.17M
Free Cash Flow(48.16M)(45.49M)(82.15M)(86.26M)(101.22M)

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.